시장보고서
상품코드
1429346

세계 바이오시밀러 시장 보고서(2024년)

Biosimilars Global Market Report 2024

발행일: | 리서치사: The Business Research Company | 페이지 정보: 영문 250 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    


■ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
■ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

바이오시밀러 시장 규모는 앞으로 수년간 빠르게 성장할 것으로 예상됩니다. 2028년 복합 연간 성장률(CAGR) 17.4%를 나타낼 전망이며 358억 1,000만 달러로 성장할 것으로 예상됩니다. 예상되는 성장의 원동력은 암 유병률 증가, 과립구 콜로니 자극 인자(G-CSF) 예방에 대한 수요 증가, 의료비 증가, 신흥국의 큰 가능성, 기술 진보, 생물학 적 제제의 보급, 인구의 고령화, 의료 접근의 개선 등의 요인입니다. 예측기간의 주요 동향으로는 혁신적인 의약품의 연구개발에 주력, 성장을 위한 M&A의 중시, 전략적 파트너십 확립, 투자 증가, 인공지능 활용 등을 들 수 있습니다.

바이오시밀러 시장은 관절염, 천식, 암 등 만성 질환의 만연으로 인해 큰 성장이 예상되고 있습니다. 장시간 노동, 제한된 신체 활동, 건강에 해로운 라이프스타일 선택 등의 요인이 이러한 증상의 발생 증가에 기여하고 있으며, 바이오시밀러가 치료 옵션으로 선호되는 경우가 늘고 있습니다. 바이오시밀러는 암세포에 대한 면역계의 반응을 자극하고 몸에서 암세포의 제거를 돕는데 중요한 역할을 합니다. 유엔의 예측에 따르면 2030년까지 만성질환이 세계 사망의 약 70%를 차지할 것으로 추정되고 만성질환에 의한 세계 부담은 약 60%를 나타낼 것으로 예상되고 있습니다. 그 결과 이 만성질환 유병률의 급증으로 바이오시밀러 수요가 높아져 바이오시밀러 시장이 추진하게 됩니다.

헬스케어비 상승 궤도는 바이오시밀러 시장 확대의 촉매가 될 수 있습니다. 헬스케어 지출에는 특정 인구 또는 헬스케어 시스템 내에서 헬스케어 제품 및 서비스에 대한 지출의 합계가 포함됩니다. 바이오시밀러 제품은 비용이 많이 드는 생물학적 제형을 대체하는 보다 비용 효율적인 대안을 제공함으로써 건강 관리 지출을 억제하는데 기여하여 환자와 의료 시스템 모두의 치료 비용을 절감 합니다. 예를 들어 영국에 본사를 둔 국가 통계국의 2023년 5월 보고서에 따르면 영국의 건강 관리 지출은 2020년과 2021년 사이에 명목 9.4% 증가, 실질 9.7% 증가했습니다. 이 건강 관리 지출의 급증은 바이오 시밀러 시장의 성장의 원동력이되었습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 거시경제 시나리오

  • 고인플레이션이 시장에 미치는 영향
  • 우크라이나,러시아 전쟁이 시장에 미치는 영향
  • COVID-19에 의한 시장에 대한 영향

제5장 세계 시장 규모와 성장

  • 세계 시장 성장 촉진요인과 억제요인
    • 시장 성장 촉진요인
    • 시장 성장 억제요인
  • 세계 시장 규모 실적과 성장(2018년-2023년)
  • 세계 시장 규모 예측과 성장(2023년-2028년, 2033년)

제6장 시장 세분화

  • 세계 바이오시밀러 시장, 유형별 세분화, 분석 및 예측(2018년-2023년, 2023년-2028년, 2033년)
  • 단클론항체
  • 인슐린
  • 에리스로포이에틴
  • 과립구 콜로니 자극 인자
  • 기타 호르몬
  • 기타 유형
  • 세계 바이오시밀러 시장 : 제품별 세분화, 분석 및 예측(2018년-2023년, 2023년-2028년, 2033년)
  • 재조합 비글리코실화 단백질
  • 재조합 글리코실화 단백질
  • 세계 바이오시밀러 시장 : 용도별 세분화, 분석 및 예측(2018년-2023년, 2023년-2028년, 2033년)
  • 종양학
  • 만성질환 및 자가면역질환
  • 성장 호르몬 결핍증
  • 감염증
  • 기타 용도

제7장 지역 및 국가 분석

  • 세계 바이오시밀러 시장 : 지역별, 분석 및 예측(2018년-2023년, 2023년-2028년, 2033년)
  • 세계 바이오시밀러 시장 : 국가별, 분석 및 예측(2018년-2023년, 2023년-2028년, 2033년)

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

  • 바이오시밀러 시장 경쟁 구도
  • 바이오시밀러 시장 기업 프로파일
    • Amgen
    • Pfizer
    • Novartis AG
    • Samsung Bioepis Co., Ltd.
    • Viatris

제31장 기타 선도적이고 혁신적인 기업

  • Biocon
  • Celltrion, Inc.
  • Coherus Biosciences
  • Elli Lilly and Company
  • Dr. Reddy's Laboratories
  • Roche India Pvt Ltd
  • Abbott India Limited
  • bioMerieux India
  • Becton Dickinson Private Limited
  • Danaher Corporation
  • Wuxi biologics
  • shanghai Henlius biotech
  • Innovent Biologics
  • Hisun Pharma
  • 3SBio

제32장 경쟁 벤치마킹

제33장 경쟁 대시보드

제34장 주요 인수합병(M&A)

제35장 미래 전망과 가능성 분석

제36장 부록

BJH 24.03.21

Biosimilars are medications made from living things, though they can be made in a variety of ways and with slightly different materials. Due to the intricacy and high cost of their creation, as well as their molecular size and structure, biosimilars are fundamentally distinct from generic drugs.

The main types of biosimilars are human growth hormone, erythropoietin, monoclonal antibodies, insulin, interferon, granulocyte-colony stimulating factor, and others. Erythropoietin is a hormone produced by the kidneys to stimulate the production and maintenance of vital red blood cells. The various products include recombinant non-glycosylated proteins and recombinant glycosylated proteins that are used for the treatment of oncology, chronic and autoimmune diseases, growth hormone deficiency, infectious diseases, and others.

The biosimilars market research report is one of a series of new reports from The Business Research Company that provides biosimilars market statistics, including biosimilars industry global market size, regional shares, competitors with a biosimilars market share, detailed biosimilars market segments, market trends, and opportunities, and any further data you may need to thrive in the biosimilars industry. This biosimilars market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The biosimilars market size has grown rapidly in recent years. It will grow from $15.86 billion in 2023 to $18.85 billion in 2024 at a compound annual growth rate (CAGR) of 18.9%. The growth observed during the historic period can be attributed to factors such as an increase in cancer prevalence, robust economic growth in emerging markets, a rise in pharmaceutical research and development (R&D) expenditure, increased healthcare spending, growing government initiatives, a strong pipeline of drugs, the cost-effectiveness of biosimilars, and an increase in patent expiration.

The biosimilars market size is expected to see rapid growth in the next few years. It will grow to $35.81 billion in 2028 at a compound annual growth rate (CAGR) of 17.4%. The forecasted growth is driven by factors such as the increasing prevalence of cancer, rising demand for granulocyte colony-stimulating factor (G-CSF) prophylaxis, higher healthcare expenditure, the significant potential of emerging economies, technological advancements, widespread use of biological drugs, an aging population, and improved healthcare access. Key trends in the forecast period include a focus on robust research and development for innovative drugs, emphasis on mergers and acquisitions for growth, establishment of strategic partnerships, increased investments, and utilization of artificial intelligence.

The biosimilars market is anticipated to witness significant growth due to the escalating prevalence of chronic diseases such as arthritis, asthma, and cancer. Factors such as prolonged work hours, limited physical activity, and unhealthy lifestyle choices contribute to the increased occurrence of these conditions, for which biosimilars are increasingly becoming a preferred treatment option. Biosimilars play a crucial role in stimulating the immune system response against cancer cells, aiding in their elimination from the body. As per a United Nations projection, by 2030, chronic diseases are estimated to account for around 70% of global deaths, with the global burden of chronic disease expected to reach approximately 60%. Consequently, this upsurge in chronic disease prevalence is set to drive the demand for biosimilars, consequently propelling the biosimilars market.

The upward trajectory of healthcare expenditures is poised to be a catalyst for the expansion of the biosimilars market. Healthcare expenditures encompass the total spending on healthcare goods and services within a specific population or healthcare system. Biosimilar products contribute to curbing healthcare expenditures by providing more cost-effective alternatives to expensive biologic drugs, thereby reducing treatment expenses for both patients and healthcare systems. For example, according to a report from the UK-based Office for National Statistics in May 2023, healthcare spending in the UK witnessed a nominal increase of 9.4% and a real increase of 9.7% between 2020 and 2021. This surge in healthcare expenditures is a driving force behind the growth of the biosimilars market.

Key players in the biosimilars market are heavily invested in pioneering innovative products to establish a competitive edge. Notably, AMJEVITA marks a significant milestone as the inaugural U.S. biosimilar to Humira, a medication relied upon by over a million patients managing severe inflammatory conditions. In January 2023, Amgen Inc., a prominent biotechnology company, introduced AMJEVITA (adalimumab-atto) into the U.S. market. This biosimilar, available at 55% and 5% below the list price of Humira, offers patients a more cost-effective option.

Major companies within the biosimilars domain persist in crafting novel solutions. FYLNETRA represents a leap forward as a leukocyte growth factor designed to lower infection incidence, particularly febrile neutropenia, in patients with non-myeloid malignancies undergoing myelosuppressive anti-cancer treatments. In May 2023, Amneal Pharmaceuticals Inc., a distinguished pharmaceutical entity, launched the commercial debut of FYLNETRA (pegfilgrastim-pbbk), a Neulasta-referenced biosimilar delivered in a pre-filled single-dose syringe. FYLNETRA aims to address neutropenia, commonly experienced by chemotherapy patients, presenting a significant advancement in biosimilar-based treatments.

In November 2022, Biocon Biologics Ltd., an Indian biopharmaceutical company, announced the acquisition of Viatris Inc.'s biosimilars business for $3 billion. This strategic move aims to enhance Biocon Biologics' proximity to patients, customers, and payors by providing direct commercial capabilities and supporting infrastructure in advanced countries and various emerging regions. The merger combines Viatris' acquired global biosimilars business with Biocon Biologics' existing capabilities in research and development, global-scale manufacturing, and commercialization. Viatris Inc. is a US-based pharmaceutical company specializing in the development, licensing, manufacturing, marketing, and distribution of generic and branded medicines.

Major companies operating in the biosimilars market report are Amgen, Pfizer, Novartis AG, Samsung Bioepis Co., Ltd., Viatris, Biocon, Celltrion, Inc., Coherus Biosciences, Elli Lilly and Company, Dr. Reddy's Laboratories, Roche India Pvt Ltd., Abbott India Limited, bioMerieux India, Becton Dickinson Private Limited, Danaher Corporation, Wuxi biologics, shanghai Henlius biotech, Innovent Biologics, Hisun Pharma, 3SBio, Beijing ShuangLu Pharmaceuticals, Qilu Pharmaceutical, Mylan, Kyowa Hakko Kirin, Takeda, Mitsubishi Tanabe, AGC Biologics, Bio-Thera, Sandoz Pty Ltd., Apotex Pty Ltd., Cadila Pharmaceuticals, BiosanaPharma, GlaxoSmithKline, AstraZeneca, Bayer, Merck, Boehringer Ingelheim, Sanofi, Fresenius Kabi, Napp Pharmaceuticals, Mundipharma Deutschland GmbH & Co. KG, HARMONIE MEDICAL SERVICE Saint-Benoit, INSULET FRANCE SAS Paris, Microgen, Geropharm, Valenta, NovaMedica, SynBio, Rani Therapeutics, Emisphere Technologies, Inc., Enteris BioPharma, Allena Pharmaceuticals, Abbvie, Johnson & Johnson, Biogen Inc., Ache, Eurofarma, Teva Pharmaceuticals, Oramed Pharmaceuticals, Entera Bio, Julphar, Hikma Pharmaceuticals, BIOPHARMA-MEA, NeoTX, AID Genomics Limited, Altis Biologics, Cipla Medpro South Africa, Next Biosciences, Viome, Inqaba Biotechnical Industries (Pty)

North America was the largest region in the global biosimilars market in 2023. Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the biosimilars market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain

The biosimilars market consists of sales of binocrit, epoetin alfa hexal, and abseamed. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Biosimilars Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on biosimilars market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for biosimilars? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The biosimilars market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

  • 1) By Type: Monoclonal Antibodies; Insulin; Erythropoietin; Granulocyte-Colony Stimulating Factor; Other Hormones; Others
  • 2) By Product: Recombinant Non-glycosylated Proteins; Recombinant Glycosylated Proteins
  • 3) By Application: Oncology; Chronic And Autoimmune Diseases; Growth Hormone Deficiency; Infectious Diseases; Other Applications
  • Companies Mentioned: Amgen; Pfizer; Novartis AG; Samsung Bioepis Co., Ltd.; Viatris
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Biosimilars Market Characteristics

3. Biosimilars Market Trends And Strategies

4. Biosimilars Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Biosimilars Market Size and Growth

  • 5.1. Global Biosimilars Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Biosimilars Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Biosimilars Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Biosimilars Market Segmentation

  • 6.1. Global Biosimilars Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Monoclonal Antibodies
  • Insulin
  • Erythropoietin
  • Granulocyte-Colony Stimulating Factor
  • Other Hormones
  • Other Types
  • 6.2. Global Biosimilars Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Recombinant Non-glycosylated Proteins
  • Recombinant Glycosylated Proteins
  • 6.3. Global Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Oncology
  • Chronic and Autoimmune Diseases
  • Growth Hormone Deficiency
  • Infectious Diseases
  • Other Applications

7. Biosimilars Market Regional And Country Analysis

  • 7.1. Global Biosimilars Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Biosimilars Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Biosimilars Market

  • 8.1. Asia-Pacific Biosimilars Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Biosimilars Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Biosimilars Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Biosimilars Market

  • 9.1. China Biosimilars Market Overview
  • 9.2. China Biosimilars Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Biosimilars Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Biosimilars Market

  • 10.1. India Biosimilars Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Biosimilars Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Biosimilars Market

  • 11.1. Japan Biosimilars Market Overview
  • 11.2. Japan Biosimilars Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Biosimilars Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Biosimilars Market

  • 12.1. Australia Biosimilars Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Biosimilars Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Biosimilars Market

  • 13.1. Indonesia Biosimilars Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Biosimilars Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Biosimilars Market

  • 14.1. South Korea Biosimilars Market Overview
  • 14.2. South Korea Biosimilars Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Biosimilars Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Biosimilars Market

  • 15.1. Western Europe Biosimilars Market Overview
  • 15.2. Western Europe Biosimilars Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Biosimilars Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Biosimilars Market

  • 16.1. UK Biosimilars Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Biosimilars Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Biosimilars Market

  • 17.1. Germany Biosimilars Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Biosimilars Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Biosimilars Market

  • 18.1. France Biosimilars Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Biosimilars Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Biosimilars Market

  • 19.1. Italy Biosimilars Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Biosimilars Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Biosimilars Market

  • 20.1. Spain Biosimilars Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Biosimilars Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Biosimilars Market

  • 21.1. Eastern Europe Biosimilars Market Overview
  • 21.2. Eastern Europe Biosimilars Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Biosimilars Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Biosimilars Market

  • 22.1. Russia Biosimilars Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Biosimilars Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Biosimilars Market

  • 23.1. North America Biosimilars Market Overview
  • 23.2. North America Biosimilars Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Biosimilars Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Biosimilars Market

  • 24.1. USA Biosimilars Market Overview
  • 24.2. USA Biosimilars Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Biosimilars Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Biosimilars Market

  • 25.1. Canada Biosimilars Market Overview
  • 25.2. Canada Biosimilars Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Biosimilars Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Biosimilars Market

  • 26.1. South America Biosimilars Market Overview
  • 26.2. South America Biosimilars Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Biosimilars Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Biosimilars Market

  • 27.1. Brazil Biosimilars Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Biosimilars Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Biosimilars Market

  • 28.1. Middle East Biosimilars Market Overview
  • 28.2. Middle East Biosimilars Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Biosimilars Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Biosimilars Market

  • 29.1. Africa Biosimilars Market Overview
  • 29.2. Africa Biosimilars Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Biosimilars Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Biosimilars Market Competitive Landscape And Company Profiles

  • 30.1. Biosimilars Market Competitive Landscape
  • 30.2. Biosimilars Market Company Profiles
    • 30.2.1. Amgen
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Pfizer
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Novartis AG
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Samsung Bioepis Co., Ltd.
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Viatris
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Biosimilars Market Other Major And Innovative Companies

  • 31.1. Biocon
  • 31.2. Celltrion, Inc.
  • 31.3. Coherus Biosciences
  • 31.4. Elli Lilly and Company
  • 31.5. Dr. Reddy's Laboratories
  • 31.6. Roche India Pvt Ltd
  • 31.7. Abbott India Limited
  • 31.8. bioMerieux India
  • 31.9. Becton Dickinson Private Limited
  • 31.10. Danaher Corporation
  • 31.11. Wuxi biologics
  • 31.12. shanghai Henlius biotech
  • 31.13. Innovent Biologics
  • 31.14. Hisun Pharma
  • 31.15. 3SBio

32. Global Biosimilars Market Competitive Benchmarking

33. Global Biosimilars Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Biosimilars Market

35. Biosimilars Market Future Outlook and Potential Analysis

  • 35.1 Biosimilars Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Biosimilars Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Biosimilars Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제